thioguanine-anhydrous has been researched along with Carcinoma--Pancreatic-Ductal* in 1 studies
1 other study(ies) available for thioguanine-anhydrous and Carcinoma--Pancreatic-Ductal
| Article | Year |
|---|---|
A drug-repositioning screen for primary pancreatic ductal adenocarcinoma cells identifies 6-thioguanine as an effective therapeutic agent for TPMT-low cancer cells.
Pancreatic cancer is one of the most difficult cancers to cure due to the lack of early diagnostic tools and effective therapeutic agents. In this study, we aimed to isolate new bioactive compounds that effectively kill pancreatic ductal adenocarcinoma (PDAC) cells, but not untransformed, human pancreatic ductal epithelial (HPDE) cells. To this end, we established four primary PDAC cell lines and screened 4141 compounds from four bioactive-compound libraries. Initial screening yielded 113 primary hit compounds that caused over a 50% viability reduction in all tested PDAC cells. Subsequent triplicate, dose-dependent analysis revealed three compounds with a tumor cell-specific cytotoxic effect. We found that these three compounds fall into a single category of thiopurine biogenesis. Among them, 6-thioguanine (6-TG) showed an IC Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Evaluation, Preclinical; Gemcitabine; Humans; MAP Kinase Signaling System; Methyltransferases; Pancreatic Neoplasms; Proto-Oncogene Proteins B-raf; Signal Transduction; Thioguanine; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |